Skip to main content
. 2018 May 3;9:51–63. doi: 10.1016/j.omto.2018.04.004

Figure 6.

Figure 6

Memory T Cells Are Enriched in Spleen and Tumor of Mice Treated with SV-NYESO1 in Combination with Anti-PD-1, Providing Long-Term Immunity against Closely Related Tumors

(A and B) Memory phenotype of T cells was characterized in spleen and tumor from indicated groups by flow cytometry by gating on CD3+ cells. The percentage of T cells expressing CD62L and/or CD44 was analyzed and shown as contour plots and pie charts, summarizing data from two independent experiments. (A) Splenocytes were harvested 3 and 13 weeks after the beginning of treatment from indicated groups (n = 8 mice per group). (B) Tumors were harvested 3 weeks after the beginning of treatment from indicated groups (n = 5–8 mice per group). (C) Treatment schema. Tumor-cured mice after SV therapy were rechallenged with the same cancer CT26.Fluc.NYESO1 at more than 150 days after the last SV treatment, and tumor growth was analyzed every day by noninvasive bioluminescent imaging. (D) Survival plots of naive (control, n = 5) and tumor-cured mice (n = 11) after rechallenge with CT26.Fluc.NYESO1 (n = 7) or CT26.Fluc.LacZ (n = 4). Statistical significance between tumor-cured and control (naive) mice was determined with the Mantel-Cox text. n.s. > 0.05, ***p ≤ 0.001.